HC Wainwright Issues Positive Forecast for Krystal Biotech (NASDAQ:KRYS) Stock Price

Krystal Biotech (NASDAQ:KRYS - Get Free Report) had its target price raised by equities researchers at HC Wainwright from $221.00 to $240.00 in a research report issued on Monday,Benzinga reports. The firm presently has a "buy" rating on the stock. HC Wainwright's price objective points to a potential upside of 44.44% from the company's current price. HC Wainwright also issued estimates for Krystal Biotech's FY2026 earnings at $6.30 EPS, FY2027 earnings at $8.56 EPS and FY2028 earnings at $9.85 EPS.

Other analysts also recently issued research reports about the stock. Jefferies Financial Group began coverage on shares of Krystal Biotech in a report on Wednesday, March 5th. They set a "buy" rating and a $245.00 price objective on the stock. Citigroup upped their price target on Krystal Biotech from $206.00 to $215.00 and gave the stock a "neutral" rating in a report on Thursday, February 20th. Chardan Capital lifted their price objective on Krystal Biotech from $212.00 to $218.00 and gave the stock a "buy" rating in a report on Thursday, February 20th. Finally, Cantor Fitzgerald reissued an "overweight" rating and issued a $215.00 target price on shares of Krystal Biotech in a report on Thursday, February 20th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $222.71.

Krystal Biotech Stock Up 0.3 %

NASDAQ KRYS traded up $0.47 during trading hours on Monday, hitting $166.16. 228,173 shares of the stock were exchanged, compared to its average volume of 295,181. Krystal Biotech has a 12-month low of $141.72 and a 12-month high of $219.34. The stock has a 50-day moving average of $174.92 and a 200 day moving average of $171.30. The company has a market cap of $4.80 billion, a price-to-earnings ratio of 55.57 and a beta of 0.79.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its quarterly earnings results on Monday, February 24th. The company reported $1.52 earnings per share for the quarter, beating analysts' consensus estimates of $1.29 by $0.23. The firm had revenue of $91.10 million for the quarter, compared to the consensus estimate of $91.35 million. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The company's revenue for the quarter was up 116.4% compared to the same quarter last year. During the same period in the previous year, the business earned $0.30 earnings per share. On average, equities research analysts expect that Krystal Biotech will post 6.14 earnings per share for the current year.

Insiders Place Their Bets

In other news, CAO Kathryn Romano sold 750 shares of the firm's stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $175.22, for a total transaction of $131,415.00. Following the sale, the chief accounting officer now owns 12,604 shares in the company, valued at $2,208,472.88. This trade represents a 5.62 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Suma Krishnan sold 25,000 shares of the company's stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $177.79, for a total value of $4,444,750.00. Following the completion of the transaction, the insider now owns 1,463,711 shares of the company's stock, valued at $260,233,178.69. The trade was a 1.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 13.70% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Fifth Third Bancorp increased its position in Krystal Biotech by 159.1% during the first quarter. Fifth Third Bancorp now owns 171 shares of the company's stock worth $31,000 after purchasing an additional 105 shares during the last quarter. Wilmington Savings Fund Society FSB purchased a new stake in shares of Krystal Biotech during the 3rd quarter valued at $40,000. GF Fund Management CO. LTD. acquired a new stake in shares of Krystal Biotech during the 4th quarter worth $95,000. GAMMA Investing LLC raised its position in shares of Krystal Biotech by 179.3% in the 1st quarter. GAMMA Investing LLC now owns 673 shares of the company's stock worth $121,000 after buying an additional 432 shares during the period. Finally, Covestor Ltd boosted its holdings in Krystal Biotech by 972.7% in the fourth quarter. Covestor Ltd now owns 708 shares of the company's stock valued at $111,000 after acquiring an additional 642 shares during the last quarter. Institutional investors and hedge funds own 86.29% of the company's stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).